| Q34388722 | A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria |
| Q28476638 | A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs |
| Q33982091 | Activities and conformational fitting of 1,4-naphthoquinone derivatives and other cyclic 1,4-diones tested in vitro against Pneumocystis carinii |
| Q34107885 | Antiparasitic agent atovaquone |
| Q33893391 | Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand |
| Q35201039 | Atovaquone-proguanil for prophylaxis and treatment of malaria. |
| Q24245639 | Atovaquone-proguanil for treating uncomplicated malaria |
| Q24247829 | Atovaquone-proguanil for treating uncomplicated malaria |
| Q35091955 | Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria |
| Q91592473 | Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling |
| Q74311319 | Automated solid-phase extraction method for the determination of atovaquone in plasma and whole blood by rapid high-performance liquid chromatography |
| Q88150621 | Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride |
| Q46705598 | Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis |
| Q47930777 | Cytogenetic and oxidative status of human lymphocytes after exposure to clinically relevant concentrations of antimalarial drugs atovaquone and proguanil hydrochloride in vitro |
| Q47980857 | Delivery of atovaquone and proguanil across sublingual membranes, in vitro |
| Q24554424 | Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports |
| Q35840856 | First case of emergence of atovaquone resistance in Plasmodium falciparum during second-line atovaquone-proguanil treatment in South America |
| Q34301638 | In vitro and in vivo interactions between miltefosine and other antileishmanial drugs |
| Q42565032 | Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration |
| Q34547922 | Modern chemotherapeutic options for malaria |
| Q39474607 | Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site |
| Q36591926 | Peer-reviewed publication of clinical trials completed for pediatric exclusivity |
| Q38627882 | Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods |
| Q42643524 | Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates |
| Q40588088 | Recent Advances and New Challenges in Travel Medicine |
| Q39533006 | Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand |
| Q28480979 | The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites |
| Q28079877 | The influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic review |
| Q41921939 | The mosquito transmission of malaria: the effects of atovaquone-proguanil (Malarone) and chloroquine |
| Q39288374 | The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women |
| Q44573293 | The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria |